Reports Q1 revenue EUR 6.5M vs. EUR 75.0M last year. The year-over-year decrease in revenue was primarily driven by the deferred income related to the Gilead drug discovery platform being fully released in revenue at the end of 2025. “Having joined the company just one year ago, I’m thrilled with our progress. I am looking forward to consummating our partnership with Gilead and adding Ouro Medicines’ talented team and its portfolio of programs to our Company,” said CEO Henry Gosebruch.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GLPG:
- Galapagos Rebrands as Lakefront Biotherapeutics and Reshapes Portfolio Around Gilead–Ouro Autoimmune Deal
- GLPG Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Galapagos Shareholders Approve Name Change to Lakefront Biotherapeutics and Broad Governance Overhaul
- Galapagos price target lowered to $28 from $33 at RBC Capital
- Galapagos Strikes New Gilead Deal to Co-Develop Gamgertamig and Unlock $500 Million for Strategic Moves